receptor antagonist (IC50
values are 16 and > 30,000 nM for CCK2
respectively). Displays anxiolytic and antipsychotic properties in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of Eli Lilly and Company
CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons.
Central nervous system characterization of the new cholecystokininB antagonist LY288513.
Helton et al.
Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons.
Rasmussen et al.
The citations listed below are publications that use Tocris products. Selected citations for LY 288513 include:
Showing Results 1 - 1 of 1